Mr. Henneman has been a member of the R1 Board since February 2016. Mr. Henneman has more than 25 years of combined financial and operational management experience in the life sciences industry. From September 2014 until November, 2018, Mr. Henneman served NewLink Genetics Corporation in various capacities, including as Chief Financial Officer until July 2018 and then as the Chief Administrative Officer. From 1998 to 2014, Mr. Henneman served Integra LifeSciences Holdings Corp., a publicly-held medical device company, in various capacities. Before becoming Integra’s Chief Financial Officer in 2007, Mr. Henneman was Chief Administrative Officer, responsible for Integra’s regulatory affairs, quality systems, clinical affairs, human resources, information systems and legal affairs functions, the management of Integra’s surgical instruments business, and Integra’s business development function. Mr. Henneman serves on the boards of directors of SeaSpine Holdings Corporation, a publicly-held medical technology company, Alafair Biosciences, Inc., a privately-held medical device company, Aprea Therapeutics Inc., a publicly-held biotechnology company, and Anika Therapeutics, Inc., a publicly-held medical device and biomaterials company. Mr. Henneman is also senior advisor to Prettybrook Partners, a private equity firm and a consultant to SparkMed Advisors LLC, which provides consulting and other services to start-up medical device and biotechnology companies. Mr. Henneman is an Investor Designee. The R1 Board believes Mr. Henneman’s senior management experience at Integra and NewLink and his service on the boards of SeaSpine, Aprea, and Anika, as well as his extensive experience in the areas of finance, financial accounting, business transactions, and mergers and acquisitions, qualify him to serve on the R1 Board.
What is John B. Henneman, III's net worth?
The estimated net worth of John B. Henneman, III is at least $858,156.60 as of August 8th, 2023. Mr. Henneman, III owns 72,114 shares of R1 RCM stock worth more than $858,157 as of April 27th. This net worth evaluation does not reflect any other assets that Mr. Henneman, III may own. Learn More about John B. Henneman, III's net worth.
How do I contact John B. Henneman, III?
Has John B. Henneman, III been buying or selling shares of R1 RCM?
John B. Henneman, III has not been actively trading shares of R1 RCM during the last quarter. Most recently, John B. Henneman III sold 50,000 shares of the business's stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $17.17, for a transaction totalling $858,500.00. Following the completion of the sale, the director now directly owns 72,114 shares of the company's stock, valued at $1,238,197.38. Learn More on John B. Henneman, III's trading history.
Who are R1 RCM's active insiders?
Are insiders buying or selling shares of R1 RCM?
In the last year, insiders at the healthcare provider sold shares 5 times. They sold a total of 109,046 shares worth more than $1,816,219.18. The most recent insider tranaction occured on March, 7th when President John M Sparby sold 10,046 shares worth more than $143,959.18. Insiders at R1 RCM own 36.8% of the company.
Learn More about insider trades at R1 RCM. Information on this page was last updated on 3/7/2024.
